CY1114192T1 - Λεντι-ιικος φορεας - Google Patents

Λεντι-ιικος φορεας

Info

Publication number
CY1114192T1
CY1114192T1 CY20131100451T CY131100451T CY1114192T1 CY 1114192 T1 CY1114192 T1 CY 1114192T1 CY 20131100451 T CY20131100451 T CY 20131100451T CY 131100451 T CY131100451 T CY 131100451T CY 1114192 T1 CY1114192 T1 CY 1114192T1
Authority
CY
Cyprus
Prior art keywords
lendi
victory
rev
packaging
upstream
Prior art date
Application number
CY20131100451T
Other languages
English (en)
Inventor
Philippa Radcliffe
James E Miskin
Fraser J Wilkes
Kyriacos A Mitrophanous
Original Assignee
Oxford Biomedica (Uk) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0202403A external-priority patent/GB0202403D0/en
Priority claimed from GB0212768A external-priority patent/GB0212768D0/en
Application filed by Oxford Biomedica (Uk) Limited filed Critical Oxford Biomedica (Uk) Limited
Publication of CY1114192T1 publication Critical patent/CY1114192T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Ένα πολυκιστρονικό γονιδίωμα ρετροϊικού φορέα που περιέχει μία πρώτη αλληλουχία νουκλεϊκού οξέος, ανοδικά ενός εσωτερικού ρυθμιστικού στοιχείου, ώστε να αυξάνεται το επίπεδο του διαθέσιμου για πακετάρισμα γονιδιωματικού RNA με την απουσία του rev, ή ενός λειτουργικού ισοδύναμου αυτού.
CY20131100451T 2002-02-01 2013-06-06 Λεντι-ιικος φορεας CY1114192T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0202403A GB0202403D0 (en) 2002-02-01 2002-02-01 Method
GB0212768A GB0212768D0 (en) 2002-05-31 2002-05-31 Method
EP03734767.1A EP1504108B1 (en) 2002-02-01 2003-02-03 Lentiviral vector

Publications (1)

Publication Number Publication Date
CY1114192T1 true CY1114192T1 (el) 2016-08-31

Family

ID=27665368

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100451T CY1114192T1 (el) 2002-02-01 2013-06-06 Λεντι-ιικος φορεας

Country Status (9)

Country Link
EP (2) EP2348119B1 (el)
JP (2) JP4598398B2 (el)
AU (1) AU2003238456A1 (el)
CY (1) CY1114192T1 (el)
DK (2) DK1504108T3 (el)
ES (2) ES2634424T3 (el)
PT (1) PT1504108E (el)
SI (1) SI1504108T1 (el)
WO (1) WO2003064665A2 (el)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2348119B1 (en) * 2002-02-01 2017-04-26 Oxford BioMedica (UK) Limited Multicistronic lentiviral vector
DK2002003T3 (en) 2005-05-27 2016-03-21 Ospedale San Raffaele Srl Gene vector comprising miRNA
WO2007014363A2 (en) * 2005-07-27 2007-02-01 Genentech, Inc. Vectors for inducible expression of hairpin rna and use thereof
US8765146B2 (en) 2005-08-31 2014-07-01 Genvec, Inc. Adenoviral vector-based malaria vaccines
GB0526210D0 (en) 2005-12-22 2006-02-01 Oxford Biomedica Ltd Vectors
JP5559185B2 (ja) * 2008-11-11 2014-07-23 オックスフォード バイオメディカ（ユーケー）リミテッド 方法
GB201118636D0 (en) 2011-10-28 2011-12-07 Oxford Biomedica Ltd Nucleotide sequence
GB201318804D0 (en) * 2013-10-24 2013-12-11 Adaptimmune Ltd Vectors for transgene expression
GB201322798D0 (en) 2013-12-20 2014-02-05 Oxford Biomedica Ltd Production system
RU2716991C2 (ru) 2014-11-05 2020-03-17 Вояджер Терапьютикс, Инк. Полинуклеотиды aadc для лечения болезни паркинсона
GB2540786A (en) * 2015-07-28 2017-02-01 Glaxosmithkline Ip Dev Ltd Codon optimised tet repressor proteins
EP3380620A1 (en) 2015-11-23 2018-10-03 Novartis AG Optimized lentiviral transfer vectors and uses thereof
FR3044017B1 (fr) 2015-11-24 2019-05-03 Glaxosmithkline Intellectual Property Development Limited Procede de transfection transitoire pour la production retrovirale
RU2752498C2 (ru) * 2015-11-24 2021-07-28 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Стабильные клеточные линии для продуцирования ретровирусов
CN110678197A (zh) 2017-03-15 2020-01-10 牛津生物医学（英国）有限公司 方法
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
ES2951857T3 (es) 2017-12-22 2023-10-25 Oxford Biomedica Ltd Vector retroviral
EP3836956A4 (en) * 2018-08-16 2022-05-18 Spacecraft Seven, LLC METHODS FOR PRODUCING VIRAL VECTORS
WO2020106621A1 (en) * 2018-11-19 2020-05-28 Board Of Regents, The University Of Texas System A modular, polycistronic vector for car and tcr transduction
CA3133188A1 (en) 2019-03-10 2020-09-17 Oxford Biomedica (Uk) Limited Gene therapy compositions and methods for treating parkinson's disease
EP4058067A1 (en) 2019-11-12 2022-09-21 Oxford BioMedica (UK) Limited Production system
US20240052366A1 (en) 2020-02-13 2024-02-15 Oxford Biomedica (Uk) Limited Production of Lentiviral Vectors
EP4118217A1 (en) 2020-03-13 2023-01-18 Oxford BioMedica (UK) Limited Lentiviral vectors
AU2021264465A1 (en) 2020-04-27 2022-12-15 University Of Iowa Research Foundation Compositions and methods for the treatment of cystic fibrosis
GB202007199D0 (en) 2020-05-15 2020-07-01 Oxford Biomedica Ltd Viral vector production
IL300219A (en) * 2020-08-03 2023-03-01 Prevail Therapeutics Inc Parkin-encoding AAV vectors and uses thereof
GB202017725D0 (en) 2020-11-10 2020-12-23 Oxford Biomedica Ltd Method
GB202114530D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Retroviral vectors
GB202114529D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral vectors
GB202114532D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral Vectors
GB202114528D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral vectors
GB202114534D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Novel viral regulatory elements
GB202117844D0 (en) 2021-12-09 2022-01-26 Oxford Biomedica Ltd Purification method
GB202211935D0 (en) 2022-08-16 2022-09-28 Oxford Biomedica Ltd envelope proteins

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6075190A (en) 1989-06-30 1991-01-17 Regents Of The University Of California, The Retrovirus detection
EP1285967A3 (en) 1990-09-21 2005-03-02 Chiron Corporation Human retroviral packaging cell line
DE4228458A1 (de) * 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
US5834256A (en) 1993-06-11 1998-11-10 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
EP0758397B1 (en) 1994-04-29 2005-06-22 Baxter Healthcare S.A. Recombinant poxviruses with foreign polynucleotides in essential regions
WO1996009400A1 (en) 1994-09-19 1996-03-28 Systemix, Inc. Methods for genetically modifying hematopoietic stem cells
AU716045B2 (en) 1994-11-28 2000-02-17 Genetic Therapy, Inc. Vectors for tissue-specific replication
GB9510272D0 (en) 1995-05-22 1995-07-19 Isis Innovation Retroviral vectors
WO1997014809A2 (en) * 1995-10-16 1997-04-24 Dana-Farber Cancer Institute Novel expression vectors and methods of use
WO1997017457A2 (en) 1995-11-08 1997-05-15 Whitehead Institute For Biomedical Research Stable packaging cell line producing pseudotyped retroviruses
US6133027A (en) 1996-08-07 2000-10-17 City Of Hope Inducible expression system
US5739018A (en) 1996-08-07 1998-04-14 The Regents Of The University Of California Packaging cell lines for pseudotyped retroviral vectors
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
CZ137399A3 (cs) 1996-10-17 1999-07-14 Oxford Biomedica (Uk) Limited Retrovirový produkční systém pro produkci replikačně defektivních vektorovýh partikulí
GB9621680D0 (en) 1996-10-17 1996-12-11 Oxford Biomedica Ltd Lentiviral vectors
WO1999032646A1 (en) * 1997-12-22 1999-07-01 Oxford Biomedica (Uk) Limited Equine infectious anaemia virus (eiav) based
GB9710807D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
GB9720465D0 (en) 1997-09-25 1997-11-26 Oxford Biomedica Ltd Dual-virus vectors
WO1999040930A1 (en) 1998-02-12 1999-08-19 Center For Blood Research, Inc. Specific inhibitors of nfat activation by calcineurin and their use in treating immune-related diseases
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
CA2322664A1 (en) 1998-03-06 1999-09-10 Oxford Biomedica (Uk) Limited Enhanced prodrug activation
CN1325653C (zh) 1998-05-22 2007-07-11 牛津生物医学（英国）有限公司 逆转录病毒传递系统
DE69839970D1 (de) 1998-11-10 2008-10-16 Univ Rochester Methoden zu herstellung von genbanken
EP1160323A1 (en) 1998-11-18 2001-12-05 Oxford Biomedica (UK) Limited 5T4 tumour-associated antigen for use in tumour immunotherapy
GB9912965D0 (en) 1999-06-03 1999-08-04 Oxford Biomedica Ltd In vivo selection method
GB0009760D0 (en) * 2000-04-19 2000-06-07 Oxford Biomedica Ltd Method
GB0024550D0 (el) * 2000-10-06 2000-11-22 Oxford Biomedica Ltd
EP2348119B1 (en) * 2002-02-01 2017-04-26 Oxford BioMedica (UK) Limited Multicistronic lentiviral vector

Also Published As

Publication number Publication date
DK1504108T3 (da) 2013-06-10
ES2411981T3 (es) 2013-07-09
EP2348119A3 (en) 2011-11-02
AU2003238456A1 (en) 2003-09-02
JP2005515783A (ja) 2005-06-02
EP1504108B1 (en) 2013-04-17
WO2003064665A2 (en) 2003-08-07
SI1504108T1 (sl) 2013-07-31
WO2003064665A3 (en) 2004-12-02
EP2348119B1 (en) 2017-04-26
EP1504108A2 (en) 2005-02-09
DK2348119T3 (en) 2017-08-21
JP4598398B2 (ja) 2010-12-15
EP2348119A2 (en) 2011-07-27
JP2010263904A (ja) 2010-11-25
PT1504108E (pt) 2013-06-12
ES2634424T3 (es) 2017-09-27
JP5601898B2 (ja) 2014-10-08

Similar Documents

Publication Publication Date Title
CY1114192T1 (el) Λεντι-ιικος φορεας
CY1121218T1 (el) Χημικες ενωσεις
ZA200603731B (en) Plasmid system for multiple expression
AR049825A1 (es) Vacuna de una subunidad prrsv
DE60038796D1 (de) Hochspezifische primer, amplifizierungsverfahren und kits
CY1105919T1 (el) Αντιμικροβιακα πολυπεπτιδια απο pseudoplectania nigrella
ATE373671T1 (de) Aminooxy-modifizierte oligonukleotide
BRPI0411897A (pt) pirroldihidroisoquinolinas como inibidores de pde10
CY1106109T1 (el) Συνθεσεις και μεθοδοι για ανιχνευση μετασχηματιστικου παραγοντος pvzmgt32 (nk 603) αραβοσιτου
CY1108344T1 (el) Φορεις εκφρασης που περιεχουν τον mcmv ie2 υποκινητη
ATE491471T1 (de) Adjuvantien für dns impstoffe basierend auf imidazochinoline
ES2243007T3 (es) Sintesis quimica completa y sintesis de genes de genomas.
BR112018010635A2 (pt) linhagens celulares estáveis para a produção retroviral
NO20070263L (no) Immunostimulerende oligonukleotidmultimerer
WO2009055005A3 (en) Competitive inhibitors of invariant chain expression and/or ectopic clip binding
PT1343838E (pt) Sistema estabilizante para a estabilizacao de polimeros que contem halogenio
TR200100003T2 (tr) Bir ya da daha çok aktif katkı maddesini içeren amin reaksiyon bileşikleri
CY1109439T1 (el) Αναλογα γλυκοπρωτεϊνικων ορμονων δισουλφιδικης σταυρωτης συνδεσης, η παρασκευη και η χρηση τους
MXPA05007586A (es) Sistema de estabilizadores para la estabilizacion de pvc.
AU2011230496A8 (en) Methods for enhancing nucleic acid hybridization
CY1113115T1 (el) Πεπτιδια - αναστολεις συντηξης του ηiv με βελτιωμενες βιολογικες ιδιοτητες
DE50115060D1 (de) Verfahren zur herstellung von alkylaminen
CY1109675T1 (el) Αντιμικροβιακα πολυπεπτιδια
BR0317284A (pt) Inibidores aminocianopiridina de proteìna quinase-2 ativada com proteìna quinase ativada com mitógeno
DE60031886D1 (de) Purinderivate